Pressmeddelande

Inhalation Sciences signs R&D order worth 257,000 SEK with major generic pharma company

Cision Publicerad: 23 Dec 2022 11:49

Inhalation Sciences AB (ISAB) has signed a new R&D contract worth 257,000 SEK (23,200 Euros) for Inhalation Research Services (IRS) work for a returning, long-standing customer – a major branded generic pharma company.

A long-standing customer of ISAB’s research services and instruments is outsourcing research and development work worth 257,000 SEK to ISAB during a peak in their development activities.

The work will be carried out using ISAB’s flexible, multi-modular PreciseInhale aerosol generation system that enables precision dosing of a range of in vitro and in vivo exposure modules.

ISAB CEO Manoush Masarrat: “We are happy to continue work with this valued customer who have such great confidence in the unique benefits and flexibility that PreciseInhale bring to their project.”

Bifogade filer

IRS order 2 dec 22 drft1 MMhttps://mb.cision.com/Main/15842/3689618/1755738.pdf

Nyheter om Inhalation Sciences

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!